Unlocking Adrenal Cortical Function Potential in South America through Partnerships

As the pharmaceutical market in South America continues to grow, there lies a vast and untapped potential for companies like Celnova Pharma and HRA RD to make their mark. With Brazil and Colombia being the only Latin American countries with market access to HRA RD's products thus far, Celnova outlines plans to expand its presence in the region through strategic partnerships and acquisitions.

In an exclusive interview with Pharmaceutical Technology, Evelina Paberžė, Chief Operating Officer of HRA RD, explained that Celnova will not only be responsible for regulatory and distribution services but also build networks with healthcare providers and patient advocacy groups to raise awareness about rare conditions such as Cushing's Syndrome and adrenocortical carcinoma.

HRA RD has already established operations in Argentina, Colombia, Chile, Peru, and Uruguay, positioning itself well for future growth. The company's focus on rare diseases, oncology, central nervous system, diabetes, and critical care has allowed it to build a strong portfolio of products.

The new partnership with Celnova will enable HRA RD to launch its rare disease products Metopirone and Lysodren in Argentina, Chile, and Peru. Both conditions often occur due to tumour growth on the adrenal glands, highlighting the importance of understanding adrenal cortical function.

Adrenocortical carcinoma is another rare condition affecting approximately one person per million each year, with Cushing's syndrome caused by an excess of cortisol in the body leading to symptoms such as depression and excess fat on the chest or stomach. HRA RD has a portfolio of three marketed drugs that treat these rare diseases.

Last May, Perrigo acquired France-based HRA in a $1.9 billion deal, further solidifying its position in the market. As the pharmaceutical industry continues to evolve, companies like Celnova Pharma and HRA RD are poised to take advantage of the growing demand for rare disease treatments. By expanding its presence in South America, HRA RD is not only unlocking new markets but also making a significant impact on the lives of patients affected by these debilitating conditions.

Adrenal cortical function